Autopsy report · NCT06015750

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

“Sponsor decision following FDA release from the PMR.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Alexion Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Hypophosphatasia

Interventions

methotrexate; rituximab; bortezomib; IVIg; Folic Acid

Participants

0

Trials that died the same way

• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (76% match in meaning)
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
  “Sponsor Decision.” (69% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (68% match in meaning)
• Single Ascending Dose Trial in Patients With Type 2 Diabetes
  “Decision by Sponsor” (68% match in meaning)
• Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
  “Industry sponsor decision” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.